Are sodium-glucose cotransporter 2 inhibitors (SGLT2Is) associated with risk of incident obstructive airway disease (OAD) and exacerbation events in clinical settings among patients with type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors (DPP4Is)? This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.